LOS ANGELES, Oct. 20, 2004 (PRIMEZONE) -- HeartSTAT Technology, Inc. (Pink Sheets:HSTA) today announced it has filed its initial Form 10KSB Annual Report with the SEC pursuant to becoming a reporting public company. Once fully reporting, HeartSTAT intends to apply for trading on OTCBB, NASDAQ or AMEX.
HeartSTAT is bringing to market the first practical system for monitoring blood flow perfusion (blood oxygen transport) and heart dynamics, which have been considered a "holy grail" for effective healthcare. Its noninvasive system addresses key issues of hospital critical care:
-- Present blood pressure (BP) and pulse oximeter preventive
monitoring devices are slow to reflect vital abnormalities, often
until it is too late.
-- Because of high risks and costs, present cardiac output blood flow
measurement is restricted to the most critical procedures on a
small number of patients.
-- Blood flow and perfusion are early and more specific indications
of patient problems; yet this monitoring been impractical.
HeartSTAT created, has patent rights for, and is applying the first science-based relationship between BP, flow and artery condition ... for measuring cardiovascular dynamics to reduce the great uncertainty that exists regarding heart disease. Initially, its new system is intended for early interventional prevention of septic shock and other conditions that kill 300,000 patients in US hospitals annually, a mortality that is almost as large as cancer. This technology is for revealing vital patient conditions that alter blood flow and are hidden with present monitoring.
Along with blood flow perfusion, this system can enable real time monitoring of heart loads and biophysics of cardiovascular disease and heart attacks. This may also open up a large internet-based physician market for preventing disease, heart attacks and managing heart failure.
The system uses the Company's FDA-cleared continuous noninvasive blood pressure (CNBP) "sensor platform," the only comfortable unrestricted technology, with disposable sensors that also allow users to purchase sensors instead of awaiting capital budget approvals. Product shipments of two models are planned in late-2005. More information is at www.HeartSTAT.com .
Statements in this release are made pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties including, without limitation, continued acceptance of the Company's services, increased levels of competition for the Company and dependence on the performance of the Management of the Company.